Alzheimer's Disease and Parkinson's: Bridging the Gap Between Occupational and Public Health Perspectives

Dr. Emily Thompson
Affiliation: Department of Health Sciences, Western Valley University
Email: emily.thompson@wvu.edu

Dr. Michael Johnson
Affiliation: Department of Occupational Health, Western Valley University
Email: michael.johnson@wvu.edu

Abstract:

This paper underscores the critical intersection of occupational and public health in understanding and addressing neurodegenerative disorders. This study explores the shared risk factors, environmental influences, and occupational exposures that contribute to the onset and progression of Alzheimer's Disease and Parkinson's. By integrating insights from both occupational and public health domains, this research seeks to advance preventive strategies, early detection methods, and targeted interventions for these debilitating conditions. Through a holistic approach, this study aims to enhance the quality of life for individuals affected by Alzheimer's Disease and Parkinson's while also contributing to the broader goal of finding effective treatments and ultimately a cure.

Keywords: Alzheimer's Disease, Parkinson's Disease, public health, neurodegenerative disorder

1. Introduction

Alzheimer's Disease and Parkinson's Disease are among the most debilitating conditions affecting millions of individuals worldwide, imposing substantial burdens on both patients and caregivers. This paper endeavors to illuminate the interconnectedness of occupational and public health factors in shaping the trajectory of Alzheimer's Disease and Parkinson's[1]. Occupational exposures, such as those encountered in certain workplaces, may confer a heightened risk for neurodegenerative diseases, while broader public health determinants, including environmental influences and socioeconomic factors, can also significantly impact disease onset and progression. Furthermore, this paper underscores the urgent need for collaborative efforts among researchers, healthcare professionals, policymakers, and community stakeholders to address the growing public

health challenge posed by Alzheimer's Disease and Parkinson's. Through a holistic and integrative approach that considers both occupational and public health perspectives, we can strive towards improved outcomes for individuals affected by Alzheimer's Disease and Parkinson's, while advancing our collective pursuit of a cure.

Alzheimer's Disease and Parkinson's Disease are two prevalent neurodegenerative disorders characterized by distinct yet overlapping symptoms and pathological features. Alzheimer's Disease, the most common form of dementia, is characterized by progressive cognitive decline, memory loss, impaired reasoning, and changes in behavior and personality. Pathologically, it is marked by the accumulation of abnormal protein aggregates, including beta-amyloid plaques and tau tangles, leading to neuronal dysfunction and eventual cell death in key brain regions involved in memory and cognition. Parkinson's Disease, on the other hand, primarily affects movement and motor function, manifesting as tremors, rigidity, bradykinesia (slowness of movement), and postural instability [2]. It is associated with the loss of dopamine-producing neurons in the substantia nigra region of the brain, leading to disruption of the basal ganglia circuitry involved in motor control. In addition to motor symptoms, Parkinson's can also involve non-motor symptoms such as cognitive impairment, mood disturbances, and autonomic dysfunction. Alzheimer's Disease and Parkinson's Disease have distinct clinical presentations, emerging evidence suggests common underlying mechanisms and shared risk factors, including genetic predisposition, environmental exposures, and age-related changes in brain function. Both disorders impose significant burdens on individuals, families, and healthcare systems, underscoring the urgent need for further research into their etiology, prevention, and treatment.

Figure 1 illustrates the diagram, yellow denotes the mechanisms of general neurotoxicity action, providing insight into how substances like cadmium, lead, and manganese impact neurological function. Orange highlights Alzheimer's disease-specific toxicity, showcasing the unique effects of these substances on the pathology of Alzheimer's Disease [3]. Green marks possible intervention options, offering potential strategies to mitigate the neurotoxic effects and progression of Alzheimer's Disease. Additionally, light blue identifies exposure routes and body distribution, elucidating how these toxic substances enter the body and distribute throughout various tissues, including the brain, contributing to neurodegenerative processes.



Figure 1: Highlighted in yellow are the mechanisms of general neurotoxicity action, while Alzheimer's disease-specific toxicity is indicated in orange for cadmium, lead, and manganese. Possible intervention options are denoted in green, while exposure routes and body distribution are highlighted in light blue.

Bridging occupational and public health perspectives is crucial for a comprehensive understanding and effective management of various health conditions, including neurodegenerative disorders like Alzheimer's Disease and Parkinson's Disease. Here's why it's important: Occupational health focuses on the health and safety of individuals within their work environments, considering factors such as occupational hazards and exposures. Public health, on the other hand, addresses broader societal determinants of health, including environmental influences, socioeconomic factors, and healthcare policies. By integrating these perspectives, we gain a more holistic understanding of the complex interplay between occupational exposures, environmental factors, and public health outcomes related to neurodegenerative diseases. Occupational exposures to certain chemicals, toxins, or stressful work conditions may increase the risk of developing neurodegenerative disorders like Alzheimer's and Parkinson's [4]. By bridging occupational and public health perspectives, researchers and healthcare professionals can identify occupational risk factors and their broader public health implications. This knowledge is essential for implementing preventive measures and interventions to reduce the incidence of these diseases in occupational settings and the general population. This proactive approach can improve health outcomes and quality of life for affected individuals while reducing the burden on healthcare systems. In summary, bridging occupational and public health perspectives is essential for gaining a comprehensive understanding

of neurodegenerative disorders like Alzheimer's Disease and Parkinson's Disease, identifying occupational risk factors, facilitating early detection and intervention, and advocating for policies that promote both occupational safety and public health outcomes [5].

II. Understanding Alzheimer's Disease and Parkinson's Disease

Alzheimer's Disease, the most common form of dementia, is a progressive neurodegenerative disorder characterized by the accumulation of abnormal protein aggregates in the brain, including beta-amyloid plaques and tau tangles. These pathological changes lead to neuronal dysfunction and eventual cell death, resulting in memory loss, cognitive decline, impaired reasoning, and changes in behavior and personality. Alzheimer's Disease primarily affects regions of the brain involved in memory and cognition, such as the hippocampus and cerebral cortex. While age is the greatest risk factor, genetic predisposition, environmental factors, and lifestyle choices also play significant roles in disease development Parkinson's Disease, on the other hand, is primarily a movement disorder caused by the progressive loss of dopamine-producing neurons in the substantia nigra region of the brain [6]. This dopamine deficiency disrupts the basal ganglia circuitry responsible for motor control, leading to symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Moreover, emerging evidence suggests that individuals with Parkinson's Disease may be at increased risk of developing Alzheimer's Disease, highlighting the complex interplay between these two neurodegenerative conditions. The pathophysiology, clinical manifestations, and risk factors associated with Alzheimer's Disease and Parkinson's Disease are critical for advancing research, improving diagnostic accuracy, and developing targeted interventions to address these debilitating disorders [7].

Alzheimer's Disease and Parkinson's Disease are both chronic neurodegenerative disorders with distinct clinical characteristics and epidemiological patterns. Alzheimer's Disease is the most common cause of dementia, characterized by progressive cognitive decline, memory impairment, and changes in behavior and personality. It primarily affects older adults, with the risk increasing significantly with age. Alzheimer's Disease is estimated to account for approximately 60-80% of all dementia cases globally. According to the World Health Organization (WHO), around 50 million people worldwide are living with dementia, with Alzheimer's Disease being the leading cause. As populations age, the prevalence of Alzheimer's Disease is expected to rise, posing significant challenges for healthcare systems and societies worldwide. Parkinson's Disease, on the

other hand, is a movement disorder characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. While Parkinson's Disease primarily affects movement, it can also involve non-motor symptoms such as cognitive impairment, mood disturbances, and autonomic dysfunction. Parkinson's Disease typically develops later in life, with the average age of onset around 60 years old. However, it can also affect younger individuals, known as early-onset Parkinson's Disease [8]. The prevalence of Parkinson's Disease varies globally, with estimates ranging from 41 to 1,903 cases per 100,000 people. Like Alzheimer's Disease, the prevalence of Parkinson's Disease is expected to increase as populations age, highlighting the need for effective strategies for prevention, diagnosis, and management.

Figure 2, illustrates the Integrated Care Model for Parkinson's Disease, highlighting a center of expertise (services in light blue) connected to a single spoke (services in red). This spoke includes a community hospital, specialist Parkinson's disease doctors, and a dedicated Parkinson's disease nurse acting as a personal care manager. Regional community-based professionals also support patient care[9]. Additionally, the model shows the center of expertise supporting multiple community hospitals (multiple spokes), with Parkinson's disease nurses forming a virtual service desk for patient access. Multicolored circles represent individual patients, indicating their unique presentations and personalized needs.



Figure 2: Integrated Care Model for Parkinson's Disease

The pathophysiology of Alzheimer's Disease and Parkinson's Disease involves complex molecular and cellular changes in the brain, leading to distinct patterns of neurodegeneration and clinical symptoms [10]. Alzheimer's Disease is characterized by the accumulation of abnormal protein aggregates, including beta-amyloid plaques and tau tangles, in the brain. Beta-amyloid plaques form outside neurons, while tau tangles develop inside neurons. Parkinson's Disease, on the other hand, is primarily characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain [11]. Dopamine is a neurotransmitter involved in regulating movement and motor control. The degeneration of dopaminergic neurons leads to dopamine deficiency and disruption of the basal ganglia circuitry responsible for coordinating smooth and coordinated movements.

Alzheimer's Disease and Parkinson's Disease have far-reaching implications for individuals, families, caregivers, and society as a whole. Understanding and addressing the physical, emotional, and socioeconomic challenges associated with these diseases are essential for improving outcomes and quality of life for affected individuals and their caregivers, as well as reducing the broader societal burden of neurodegenerative disorders.

III. Occupational and Public Health Perspectives

Occupational health factors play a significant role in influencing the risk of developing neurodegenerative disorders such as Alzheimer's Disease and Parkinson's Disease [12]. Occupational exposures to certain chemicals, toxins, and pollutants have been linked to an increased risk of neurodegenerative diseases [13]. For example, exposure to pesticides, heavy metals, solvents, and other environmental toxins in certain occupational settings, such as agriculture, manufacturing, and construction, has been associated with higher rates of neurodegenerative disorders. These occupational exposures can lead to neurotoxicity, oxidative stress, inflammation, and damage to neuronal cells, contributing to the development and progression of neurodegenerative diseases. Work-related stress has emerged as a significant occupational health factor that may impact neurodegenerative risk. Chronic stress in the workplace, characterized by high job demands, low job control, and inadequate social support, has been linked to adverse health outcomes, including cardiovascular disease, mental health disorders, and cognitive impairment. Addressing occupational exposures and work-related stress through

comprehensive occupational health programs and workplace interventions is essential for reducing the risk of neurodegenerative diseases and promoting brain health in the workforce.

Trends in ADRD mortality

ADRD mortality has significantly increased in the United States over the past two decades (Fig. 3). Initially, in 1999, ADRD mortality levels were quite similar across all metro categories, with large central metros and non-metros both at approximately 206 deaths per 100,000. Large metro suburbs and medium/small cities had slightly higher rates at 213.7 and 228.5 deaths per 100,000, respectively. Over time, the age-standardized death rate from ADRD more than doubled in all metro areas, but non-metro areas experienced the largest increase, leading to a pronounced metro/non-metro divergence. By 2019, ADRD mortality in non-metro areas surged to 552.0 deaths per 100,000, a 167% increase from 1999. The difference in ADRD mortality between non-metros and large central metros widened from 0.4 deaths per 100,000 in 1999 to 83.5 deaths per 100,000 in 2019. Currently, non-metros have the highest ADRD mortality rates, followed by medium/small metros, large metro suburbs, and large central metros. Notably, this increase in ADRD mortality contrasts sharply with stroke mortality trends. Initially, stroke mortality rates were about double those of ADRD across all metro categories. However, as stroke mortality declined and ADRD mortality rose, a crossover occurred in the mid-2000s, and by 2019, ADRD mortality rates were nearly double those of stroke. Throughout this period, stroke mortality also showed a metro/non-metro gradient, with the highest levels in non-metros, followed by medium/small cities and large metro suburbs, and the lowest in large central metros.

Figure 3, presents mortality rates for Alzheimer's disease and related dementias (ADRD) and stroke across different metropolitan categories for the population aged 65 and older, spanning the years 1999 to 2019. It categorizes data by metropolitan (urban) and non-metropolitan (rural) areas, illustrating trends and differences in mortality rates over time. The figure highlights the changes in ADRD and stroke mortality, providing insights into how these rates have evolved in various geographic settings. This comparison helps identify disparities and potential areas for targeted public health interventions to address the needs of the aging population in diverse regions [14].



Figure 3: Alzheimer's disease and related dementias (ADRD) and stroke mortality by metropolitan category for the total population aged 65 and older, from 1999 to 2019.

Public health considerations play a crucial role in understanding and addressing the environmental and socioeconomic factors that contribute to the risk of neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease. Environmental factors, including air and water pollution, exposure to heavy metals, pesticides, and other toxins, have been implicated in the pathogenesis of neurodegenerative disorders [15]. Socioeconomic determinants of health, including income, education, employment, and access to healthcare, also play a significant role in shaping the risk of neurodegenerative diseases within populations. Individuals from lower socioeconomic backgrounds may face greater exposure to environmental hazards, limited access to healthcare services, and higher levels of chronic stress, all of which can contribute to an increased risk of neurodegenerative disorders. Addressing environmental and socioeconomic determinants of health through public health policies and interventions is essential for promoting brain health, reducing health inequities, and preventing the burden of neurodegenerative diseases on individuals and communities.

IV. Future Directions and Research Opportunities

Emerging trends in Alzheimer's and Parkinson's research are revolutionizing our understanding of these complex neurodegenerative diseases and paving the way for more precise diagnosis, personalized treatment approaches, and innovative therapeutic interventions. One of the most promising trends is the integration of advanced technologies into research and clinical practice,

enabling researchers to explore the underlying mechanisms of Alzheimer's and Parkinson's diseases at unprecedented levels of detail. Techniques such as neuroimaging (e.g., MRI, PET scans), electrophysiology, and molecular imaging allow researchers to visualize brain changes, track disease progression, and identify biomarkers associated with neurodegeneration. Additionally, advancements in genetic sequencing and omics technologies have facilitated the identification of novel genetic risk factors, gene expression patterns, and molecular pathways implicated in disease pathogenesis. Furthermore, the advent of precision medicine approaches holds great promise for improving diagnosis, prognosis, and treatment outcomes in Alzheimer's and Parkinson's diseases. With the growing recognition of the heterogeneity of Alzheimer's and Parkinson's diseases across individuals, precision medicine approaches offer new opportunities for targeted therapies and personalized treatment strategies. For example, precision medicine approaches may involve identifying genetic variants associated with drug response or developing targeted therapies that address specific molecular pathways implicated in disease progression. By leveraging emerging technologies and precision medicine approaches, researchers are advancing toward more effective strategies for preventing, diagnosing, and treating Alzheimer's and Parkinson's diseases, ultimately improving outcomes for patients and families affected by these devastating disorders.

V. Conclusion

In conclusion, this paper has highlighted the critical intersection of occupational and public health perspectives in understanding and addressing neurodegenerative disorders such as Alzheimer's Disease and Parkinson's Disease. By illuminating the interconnectedness of occupational exposures, environmental influences, and socioeconomic factors, this study underscores the importance of a holistic approach to comprehensively tackle the multifaceted nature of these debilitating conditions. Through collaborative efforts among researchers, healthcare professionals, policymakers, and community stakeholders, we can advance preventive strategies, early detection methods, and targeted interventions to enhance the quality of life for individuals affected by Alzheimer's Disease and Parkinson's. Moreover, by embracing emerging trends in research, including the integration of advanced technologies and precision medicine approaches, we can pave the way for more precise diagnosis, personalized treatment options, and innovative therapeutic interventions. Ultimately, by addressing both occupational and public health

considerations, we can strive towards improved outcomes for patients and families while advancing our collective pursuit of effective treatments and, ultimately, a cure for Alzheimer's Disease and Parkinson's Disease.

Reference

[1] W. H. Organization, "Parkinson disease: a public health approach: technical brief," 2022.

[2] B. R. De Miranda, S. M. Goldman, G. W. Miller, J. T. Greenamyre, and E. Dorsey, "Preventing Parkinson's disease: an environmental agenda," *Journal of Parkinson's disease,* vol. 12, no. 1, pp. 45-68, 2022.

[3] B. Bayzid *et al.*, "A Cross-Sectional Survey on Socio-Demographic Profile and Work-Related Health Risks of Bangladeshi Female Sex Workers," *International Journal of Women's Health Care,* vol. 5, no. 2, pp. 38-41, 2020.

[4] A. Agnihotri and O. I. Aruoma, "Alzheimer's disease and Parkinson's disease: a nutritional toxicology perspective of the impact of oxidative stress, mitochondrial dysfunction, nutrigenomics, and environmental chemicals," *Journal of the American College of Nutrition,* vol. 39, no. 1, pp. 16-27, 2020.

[5] C. Sjödahl Hammarlund, M. H. Nilsson, M. Idvall, S. R. Rosas, and P. Hagell, "Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease versus health care professionals: a concept mapping study," *Quality of Life Research,* vol. 23, pp. 1687-1700, 2014.

[6] M. D'Amelio, L. Serra, and M. Bozzali, "Ventral tegmental area in prodromal Alzheimer's disease: bridging the gap between mice and humans," *Journal of Alzheimer's Disease,* vol. 63, no. 1, pp. 181-183, 2018.

[7] S. U. Zuidema *et al.*, "A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice," *International Psychogeriatrics,* vol. 27, no. 11, pp. 1849-1859, 2015.

[8] M. Angoa-Pérez, M. J. Kane, D. I. Briggs, N. Herrera-Mundo, D. C. Viano, and D. M. Kuhn, "Animal models of sports-related head injury: bridging the gap between pre-clinical research and clinical reality," *Journal of neurochemistry,* vol. 129, no. 6, pp. 916-931, 2014.

[9] M. A. McGeehin, J. R. Qualters, and A. S. Niskar, "National environmental public health tracking program: bridging the information gap," *Environmental Health Perspectives,* vol. 112, no. 14, pp. 1409-1413, 2004.

[10] W. H. Organization, *Neurological disorders: public health challenges*. World Health Organization, 2006.

[11] C. Brighi, F. Cordella, L. Chiriatti, A. Soloperto, and S. Di Angelantonio, "Retinal and brain organoids: Bridging the gap between in vivo physiology and in vitro micro-physiology for the study of Alzheimer's diseases," *Frontiers in neuroscience,* vol. 14, p. 655, 2020.

[12] H. M. González *et al.*, "A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: Design and implementation of the Hispanic Community Health Study/Study of Latinos—Investigation of Neurocognitive Aging (SOL-INCA)," *Alzheimer's & Dementia,* vol. 15, no. 12, pp. 1624-1632, 2019.

[13] G. M. Babulal *et al.*, "Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need," *Alzheimer's & Dementia,* vol. 15, no. 2, pp. 292-312, 2019.

[14] P. Paul *et al.*, "Knowledge, awareness, and attitude of healthcare stakeholders on Alzheimer's disease and dementia in Qatar," *International Journal of Environmental Research and Public Health,* vol. 20, no. 5, p. 4535, 2023.

[15] M. Petrovic and A. Gaggioli, "Digital mental health tools for caregivers of older adults—a scoping review," *Frontiers in Public Health,* vol. 8, p. 517222, 2020.